Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2017-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

"Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Nexavar to advanced Hepatocellular carcinoma patients when compared with the control group who did not receive administration of the drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of "Immuncell-LC" in TACE Therapy

NCT02856815

Carcinoma, Hepatocellular

COMPLETED PHASE2

Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

NCT00699816

Hepatocellular Carcinoma

COMPLETED PHASE3

Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea

NCT06620510

Hepatocellular Carcinoma

COMPLETED

Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

NCT03983967

Liver Transplantation

COMPLETED PHASE1/PHASE2

Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

NCT00703365

Carcinoma, Hepatocellular

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* primary outcome Compare clinical efficacy of group treated with cell therapeutic Immuncell-LC evaluated by progression free survival with that of untreated group
* secondary outcome compare clinical efficacy of group treated with Immuncell-LC, a drug for treating advanced hepatocellular carcinoma evaluated by overall survival, disease control rate, changes of Alpha Feto Protein(AFP) figures from baseline to the last observation date and that of untreated group and evaluate adverse reactions, clinical pathological tests and its safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.

Group Type NO_INTERVENTION

No interventions assigned to this group

Immuncell-LC group

The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).

Group Type EXPERIMENTAL

Immuncell-LC

Intervention Type DRUG

intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immuncell-LC

intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Activated T lymphocyte

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have consented to the study by providing signature of self, guardian or legal representative
* The patient is more than 20 and less than 80 years old
* The patient is diagnosed as hepatocellular carcinoma by pathological/radiological test and in the stage of III or IV
* Child-Pugh Score should be A
* ECOG Performance Status (ECOG-PS) is less than 2 or equal to
* Patients who receiving or ready for Nexavar treatment
* Patients who satisfy the following conditions of the blood test and kidney function test

* Absolute granulocyte count is bigger than 1,000/µL
* Hemoglobin is bigger than 8.5 g/dL
* Platelet count is bigger than 5x10\^10/L
* Blood Urea Nitrogen(BUN) or Creatinine 1.5xupper normal limit

Exclusion Criteria

* Patients who are immune deficient or have a history of auto-immune diseases (Ex. Rheumatoid Arthritism, Systemic Lupus Erythematosus, Vasculitis, Multiple sclerosis, Adolescent Insulin-Dependent Diabetes Mellitus, etc.)
* Patients who have a history of malignant tumors in the recent 5 years prior to the study with the exception of basal cell carcinoma, local prostate cancer, and cervical cancer, liver cancer.
* Patients who had anti-cancer medication before the study with the exception of Nexavar
* Patients who has serious dysfunction in other organs by sub-investigator's opinion
* Patients has serious allergic-history by sub-investigator's opinion
* Patients has serious mental disease sub-investigator's opinion
* Pregnant women, nursing mother of having intention of being pregnant during the study
* Patients who participated in other clinical trial within 4 weeks before this study

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No